Worldwide Clinical Trials Brings Rare Disease Expertise to Your Guillain-Barre Study
Guillain-Barré syndrome (GBS) and CIDP are autoimmune diseases, with symptoms ranging from temporary weakness to debilitating and potentially fatal paralysis. These rare neurological disorders affect one individual in approximately 100,000 every year. Although most people recover from the disease, they can continue to suffer weakness after recovery. Due to the rarity of the condition and the fact that it affects patients of all ages, the challenge for drug development researchers is to identify suitable patient populations.
Worldwide Clinical Trials has been involved with rare disease studies at all phases: design, execution, and analysis. This extensive practical experience, combined with the necessary expertise in trial design and execution, means Worldwide is poised to address the challenges associated with rare conditions like GBS. Rely on us for our global access to hard-to-find patient populations and our deep familiarity with regulatory concerns and potential operational issues related to rare disease studies.